| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.79.1.101 |
| P698 | PubMed publication ID | 2491971 |
| P2093 | author name string | W L Chandler | |
| G Schmer | |||
| P Angleton | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 101-106 | |
| P577 | publication date | 1989-01-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1) | |
| P478 | volume | 79 |
| Q51802826 | 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. |
| Q39422383 | ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. |
| Q28193615 | Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase |
| Q87411732 | Age and aerobic training status effects on plasma and skeletal muscle tPA and PAI-1 |
| Q80675818 | Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts |
| Q47706852 | Alterations in coagulatory and fibrinolytic systems following an ultra-marathon |
| Q41534557 | Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity |
| Q24299368 | Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization |
| Q90030308 | An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1 |
| Q39404864 | Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis. |
| Q55491477 | Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. |
| Q36125305 | Brachial artery endothelial function is stable across the morning in young men. |
| Q24290360 | CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression |
| Q71789041 | Calcium channel antagonists in the modern era of coronary thrombolysis: benefit or detriment? |
| Q40433487 | Changes in the haemostatic system after thermoneutral and hyperthermic water immersion |
| Q44851759 | Changes in von Willebrand factor and fibrinolysis following a post-exercise cool-down |
| Q48457643 | Chronobiological patterns of onset of acute cerebrovascular diseases |
| Q50779981 | Circadian Rhythms in Adipose Tissue Physiology. |
| Q37054785 | Circadian Variation of Fibrinolytic Activity in Blood |
| Q39434251 | Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors |
| Q37744499 | Circadian clock and vascular disease |
| Q33765425 | Circadian clocks and vascular function |
| Q36954738 | Circadian patterns of ST elevation myocardial infarction in the new millennium |
| Q78194801 | Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy |
| Q37510446 | Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea |
| Q36812008 | Circadian variation in fibrinolytic activity in patients with variant angina |
| Q67567705 | Circadian variation in the time of request for helicopter transport of cardiac patients |
| Q30418225 | Circadian variation of heart rate is affected by environment: a study of continuous electrocardiographic monitoring in members of a symphony orchestra |
| Q73156969 | Circadian variation of malignant ventricular arrhythmias in patients with ischemic and nonischemic heart disease after cardioverter defibrillator implantation. European 7219 Jewel Investigators |
| Q42577762 | Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. |
| Q36528563 | Coagulation markers in healthy human subjects exposed to diesel exhaust |
| Q48931831 | Comparison of general and spinal anesthesia and their influence on hemostatic markers in patients undergoing total hip arthroplasty |
| Q47694995 | Coordination of cardiac rhythmic output and circadian metabolic regulation in the heart |
| Q51543758 | Defective fibrinolysis occurs after infrainguinal reconstruction. |
| Q47406240 | Diurnal variation and effect of insulin on circulating high molecular weight (HMW) adiponectin and NF-κB activity in human endothelial cells |
| Q48724435 | Effect of a Change in the Sleep/Wake Cycle on the Diurnal Variation of Fibrinolytic Parameters |
| Q28076223 | Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk |
| Q34703186 | Effects of different protein sources on plasminogen inhibitor-1 and factor VII coagulant activity added to a fat-rich meal in type 2 diabetes |
| Q71720344 | Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors |
| Q74314747 | Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction |
| Q41760686 | Evaluating PAI-1 as a biomarker for stress in diving: human serum total PAI-1 is unaltered after 2 h dry exposures to 280 kPa hyperbaric air. |
| Q79290689 | Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1 |
| Q74098998 | Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction |
| Q42686542 | Fibrinolysis for intermediate-risk pulmonary embolism |
| Q37620112 | Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause |
| Q41040148 | Haemostasis and disseminated intravascular coagulation |
| Q37512114 | Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle |
| Q37174998 | Impact of genetic variation on perioperative bleeding |
| Q78630161 | Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia |
| Q34777275 | Influence of presentation at the weekend on treatment and outcome in ST-elevation myocardial infarction in hospitals with catheterization laboratories |
| Q33892317 | Intracellular high cholesterol content disorders the clock genes, apoptosis-related genes and fibrinolytic-related genes rhythmic expressions in human plaque-derived vascular smooth muscle cells. |
| Q38400520 | Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study |
| Q46057092 | Lower Framingham risk score and the absence of hypertension are associated with the morning peak in the circadian variation of ST-elevation myocardial infarction onset |
| Q90683623 | Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin‑induced model of liver injury |
| Q73562073 | Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours |
| Q51550276 | Partially hydrogenated soybean oil reduces postprandial t-PA activity compared with palm oil. |
| Q34220031 | Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro |
| Q88116010 | Pharmacodynamic Effects of Sulodexide on Profibrinolytic and Haemorrheological Patterns |
| Q41047260 | Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events |
| Q51775341 | Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty. |
| Q45926880 | Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina |
| Q73295877 | Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance |
| Q34384926 | Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease |
| Q34384932 | Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents |
| Q34376916 | Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. |
| Q34217461 | Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions |
| Q59709062 | Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study |
| Q34986710 | Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents |
| Q89758415 | Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions |
| Q51576071 | Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. |
| Q41047300 | Practical implications of circadian variations in thrombolytic and antithrombotic activities. |
| Q50891002 | Progressive intermittent claudication is associated with impaired fibrinolysis. |
| Q41036094 | Prospective study of endogenous tissue plasminogen activator and risk of stroke |
| Q36563164 | Protein Microarrays for Quantitative Detection of PAI-1 in Serum |
| Q77356880 | Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis |
| Q54254146 | Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. |
| Q73551754 | Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction |
| Q88947995 | Role of the circadian system in cardiovascular disease |
| Q37057437 | Sex Differences in the Impact of Shift Work Schedules on Pathological Outcomes in an Animal Model of Ischemic Stroke. |
| Q33611386 | Should we get up in the morning? Observations on circadian variations in cardiac events |
| Q38754350 | Sleep apnea in total joint arthroplasty patients and the role for cardiac biomarkers for risk stratification: an exploration of feasibility. |
| Q34172154 | Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study |
| Q58593788 | The Influence of Tissue Plasminogen Activator I/D Polymorphism on the tPA Response to Exercise |
| Q37292454 | The autonomic nervous system and ischemic stroke: a reciprocal interdependence. |
| Q73291628 | The effect of red wine on the fibrinolytic system and the cellular activation reactions before and after exercise |
| Q41176903 | The effects of acute garlic supplementation on the fibrinolytic and vasoreactive response to exercise |
| Q73810373 | The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis |
| Q37423754 | The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. |
| Q28080493 | Therapeutic applications of circadian rhythms for the cardiovascular system |
| Q34052574 | Variation of mortality after coronary artery bypass surgery in relation to hour, day and month of the procedure |
Search more.